PMDA drug package insert
サンラビン点滴静注用150mg
PMDA Prescription drug · 旭化成セラピューティクス株式会社 · package insert Apr 1, 2026
Key facts
| Brand names | サンラビン点滴静注用150mg, サンラビン点滴静注用200mg, サンラビン点滴静注用250mg |
|---|---|
| Nonproprietary names | エノシタビン |
| Companies | 製造販売元／旭化成セラピューティクス株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 抗悪性腫瘍剤 |
| Therapeutic category codes | 874224 |
| YJ codes | 4224402D1036, 4224402D2032, 4224402D3039 |
| Approval numbers | 22100AMX00510000, 22100AMX00511000, 22100AMX00512000 |
| Package insert edition | 第2版 |
| Package insert date | Apr 1, 2026 |
| PMDA document key | 100898_4224402D1036_1 |
| PMDA company code | 100898 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: